Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB

• Published in: Scientific reports Vol. 14; no. 1; p. 4314
• Main Authors: Fróes, Renata de Sá Brito, Andrade, Adriana Ribas, Faria, Mikaell Alexandre Gouvea, de Souza, Heitor Siffert Pereira, Parra, Rogério Serafim, Zaltman, Cyrla, dos Santos, Carlos Henrique Marques, Bafutto, Mauro, Quaresma, Abel Botelho, Santana, Genoile Oliveira, Luporini, Rafael Luís, de Lima Junior, Sérgio Figueiredo, Miszputen, Sender Jankiel, de Souza, Mardem Machado, Herrerias, Giedre Soares Prates, Junior, Roberto Luiz Kaiser, do Nascimento, Catiane Rios, Féres, Omar, de Barros, Jaqueline Ribeiro, Sassaki, Ligia Yukie, Saad-Hossne, Rogerio
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 21.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4020/1503/257/1389; 692/4020/1503/257/1402; Colorectal carcinoma; Comorbidity; Crohn's disease; Epidemiology; Humanities and Social Sciences; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; multidisciplinary; Patients; Registry; Science; Science (multidisciplinary); Severity; Ulcerative colitis; Brazil; Inflammatory bowel disease; Severity; Registry; Epidemiology; Ulcerative colitis; Crohn’s disease
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-54332-1

The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) established a national registry of inflammatory bowel disease (IBD). The aim of the study was to identify clinical factors associated with disease severity in IBD patients in Brazil. A population-based risk model aimed at stratifying the severity of IBD based on previous hospitalization, use of biologics, and need for surgery for ulcerative colitis (UC) and Crohn’s Disease (CD) and on previous complications for CD. A total of 1179 patients (34.4 ± 14.7y; females 59%) were included: 46.6% with UC, 44.2% with CD, and 0.9% with unclassified IBD (IBD-U). The time from the beginning of the symptoms to diagnosis was 3.85y. In CD, 41.2% of patients presented with ileocolic disease, 32% inflammatory behavior, and 15.5% perianal disease. In UC, 46.3% presented with extensive colitis. Regarding treatment, 68.1%, 67%, and 47.6% received biological therapy, salicylates and immunosuppressors, respectively. Severe disease was associated with the presence of extensive colitis, EIM, male, comorbidities, and familial history of colorectal cancer in patients with UC. The presence of Montreal B2 and B3 behaviors, colonic location, and EIM were associated with CD severity. In conclusion, disease severity was associated with younger age, greater disease extent, and the presence of rheumatic EIM.